Weight LossFDA Approved
Lixisenatide
Also known as: Adlyxin · Lyxumia
A fast-acting once-daily GLP-1 agonist specifically targeting post-meal blood sugar spikes, often combined with basal insulin.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~3 hours
Typical Dose
10–20 mcg daily
Administration
Subcutaneous injection
Mechanism of Action
Short-acting GLP-1 receptor agonist providing intense postprandial glycemic control through localized gut and pancreatic effects.
Key Research Areas
weight lossGLP-1FDA approvedpostprandial
Frequently Asked Questions
What is Lixisenatide?▾
A fast-acting once-daily GLP-1 agonist specifically targeting post-meal blood sugar spikes, often combined with basal insulin.
How does Lixisenatide work?▾
Short-acting GLP-1 receptor agonist providing intense postprandial glycemic control through localized gut and pancreatic effects.
What is the recommended dosage for Lixisenatide?▾
The typical research dosage is 10–20 mcg daily, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Lixisenatide?▾
The half-life of Lixisenatide is approximately ~3 hours. This affects dosing frequency and timing in research protocols.
Is Lixisenatide FDA approved?▾
Yes, Lixisenatide is FDA approved for specific medical indications. Consult your physician for proper medical guidance.
Research Disclaimer
The information provided about Lixisenatide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.